Back


07/06/2019
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has received constructive advice from the European Medicines Agency (EMA)’s Scientific Advice Working Group in response to the request for advice submitted to the agency. After receiving this feedback, Orphazyme confirms its intention to file the MAA for NPC in the first half of 2020. [...]

Download the pdf file





X

X